Literature DB >> 19052822

Polymorphism Arg290Arg in esophageal-cancer-related gene 1 (ECRG1) is a prognostic factor for survival in esophageal cancer.

Kai Bachmann1, Shanly Shahmiri, Jussuf Kaifi, Paulus Schurr, Oliver Mann, Tamina Rawnaq, Suzette Block, Viacheslav Kalinin, Jakob R Izbicki, Tim Strate.   

Abstract

BACKGROUND: Esophageal cancer is one of the most frequent cancers worldwide and is associated with poor outcome. Besides clinicopathological data, few prognostic molecular markers exist. Esophageal-cancer-related gene1 (ECRG1) short tandem repeats are associated with higher risk for developing esophageal squamous cell carcinoma. The aim of the present study was to evaluate the impact of DNA polymorphisms in the coding region of ECRG1 in esophageal carcinoma.
METHODS: Genomic DNA of 107 patients with esophageal cancer that underwent complete surgical resection between 1997 and 2005 was extracted. DNA was analyzed for ECRG1 polymorphisms Arg290Arg, Arg290Gln, and Gln290Gln by PCR and gel electrophoresis. Polymorphisms were correlated with survival data by the Kaplan-Meier method, multivariate Cox regression analysis, and odds ratio were determined. For all variables, cross tables were generated, followed by calculation of the p value by using the chi-square test/Fisher-exact test.
RESULTS: Follow-up data of 102 patients with esophageal cancer were available after complete surgical resection for a median follow-up time of 24.3 months. Polymorphism Arg290Arg was found in 47 patients (46.1%), Arg290Gln in 48 patients (47.0%), and Gln290Gln in seven cases (6.9%). Arg290Arg polymorphism was significantly associated with reduced overall survival (p = 0.01) and tumor-free survival (p = 0.01) by the log-rank test. Multivariate regression analysis by Cox revealed polymorphism Arg290Arg to be a significant prognostic factor for survival (p = 0.012).
CONCLUSIONS: Polymorphism Arg290Arg in ECRG1 is associated with poor clinical outcome after complete surgical resection in patients with esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19052822     DOI: 10.1007/s11605-008-0766-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  36 in total

1.  High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.

Authors:  Huan Xi; Stephan E Baldus; Ute Warnecke-Eberz; Jan Brabender; Susanne Neiss; Ralf Metzger; Frederike C Ling; Hans P Dienes; Elfriede Bollschweiler; Stefan Moenig; Rolf P Mueller; Arnulf H Hoelscher; Paul M Schneider
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

2.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

Authors:  Heiko Pohl; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

Review 3.  Esophageal cancer: a systematic review.

Authors:  R Wong; R Malthaner
Journal:  Curr Probl Cancer       Date:  2000 Nov-Dec       Impact factor: 3.187

4.  Bax expression as a prognostic marker of postoperative chemoradiotherapy for patients with esophageal cancer.

Authors:  M Ikeguchi; M Maeta; N Kaibara
Journal:  Int J Mol Med       Date:  2001-04       Impact factor: 4.101

5.  [Cloning and identification of cDNA fragments related to human esophageal cancer].

Authors:  T Su; H Liu; S Lu
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1998-07

6.  Time trends in cancer mortality in China: 1987-1999.

Authors:  Ling Yang; Donald M Parkin; Liandi Li; Yude Chen
Journal:  Int J Cancer       Date:  2003-09-20       Impact factor: 7.396

7.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

8.  Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma.

Authors:  Kuang-Tai Kuo; Kuan-Chih Chow; Yu-Chung Wu; Chen-Sung Lin; Hao-Wei Wang; Wing-Yin Li; Liang-Shun Wang
Journal:  Ann Thorac Surg       Date:  2003-09       Impact factor: 4.330

9.  Short tandem repeat polymorphism in a novel esophageal cancer-related gene (ECRG2) implicates susceptibility to esophageal cancer in Chinese population.

Authors:  Chun-mei Yue; Mei-xia Bi; Wen Tan; Da-jun Deng; Xin-yu Zhang; Li-ping Guo; Dong-xin Lin; Shih-Hsin Lu
Journal:  Int J Cancer       Date:  2004-01-10       Impact factor: 7.396

10.  Relevance of N-nitrosamines to oesophageal cancer in China.

Authors:  S H Lu; S X Chui; W X Yang; X N Hu; L P Guo; F M Li
Journal:  IARC Sci Publ       Date:  1991
View more
  3 in total

1.  A novel tumor suppressor gene ECRG4 interacts directly with TMPRSS11A (ECRG1) to inhibit cancer cell growth in esophageal carcinoma.

Authors:  Lin-wei Li; Yuan-yuan Li; Xiao-yan Li; Chun-peng Zhang; Yun Zhou; Shih-Hsin Lu
Journal:  BMC Cancer       Date:  2011-02-03       Impact factor: 4.430

2.  A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients.

Authors:  Susanne Blank; Sivaramakrishna Rachakonda; Gisela Keller; Wilko Weichert; Florian Lordick; Rupert Langer; Christoph Springfeld; Thomas Bruckner; Karen Becker; Rajiv Kumar; Katja Ott
Journal:  BMC Cancer       Date:  2014-02-03       Impact factor: 4.430

3.  Intracellular autoactivation of TMPRSS11A, an airway epithelial transmembrane serine protease.

Authors:  Ce Zhang; Yikai Zhang; Shengnan Zhang; Zhiting Wang; Shijin Sun; Meng Liu; Yue Chen; Ningzheng Dong; Qingyu Wu
Journal:  J Biol Chem       Date:  2020-07-15       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.